Advertisement
Screener

Cue Biopharma, Inc. (CUE) Price / Book

2.8 / 5 stars · 68/120 Roast Me

Cue Biopharma, Inc. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

  • Cue Biopharma, Inc. price/book ratio for the quarter ending 2026-06-30 was 71.42, a 2359.50% increase year-over-year.
  • Cue Biopharma, Inc. price/book ratio for the quarter ending 2026-03-31 was 0.03, a 99.99% decline year-over-year.
  • Cue Biopharma, Inc. price/book ratio for the quarter ending 2025-12-31 was 0.04, a 99.97% decline year-over-year.
  • Cue Biopharma, Inc. price/book ratio for the quarter ending 2025-09-30 was 4.25, a 92.12% decline year-over-year.
  • Cue Biopharma, Inc. price/book ratio for fiscal 2026 was 71.42.
  • Cue Biopharma, Inc. price/book ratio for fiscal 2025 was 0.04, a 99.97% decline from fiscal 2024.
  • Cue Biopharma, Inc. price/book ratio for fiscal 2024 was 115.52, a 14.56% increase from fiscal 2023.
  • Cue Biopharma, Inc. price/book ratio for fiscal 2023 was 100.83, a 64.06% increase from fiscal 2022.
Available history
2018-03-31 to 2026-06-30
Data captured

Historical Price/Book Ratio

DatePrice/Book RatioMarket capitalizationShareholder equity
2026-06-3071.42$164.99M$2.31M
2026-03-310.03$722,689.70$21.61M
2025-12-310.04$981,993.56$26.43M
2025-09-304.25$56.28M$13.25M
2025-06-302.9$52.73M$18.16M
2025-03-31256.77$1.69B$6.58M
2024-12-31115.52$2.02B$17.5M
2024-09-3053.9$1.37B$25.37M
2024-06-3083.69$1.81B$21.62M
2024-03-3191.82$2.76B$30.04M
2023-12-31100.83$3.74B$37.09M
2023-09-3072.97$3.11B$42.67M
2023-06-30104.12$4.79B$46M
2023-03-3184.05$4.62B$55.02M
2022-12-3161.46$4.04B$65.68M
2022-09-3046.63$2.37B$50.76M
2022-06-3044.23$2.64B$59.76M
2022-03-3177.36$5B$64.67M
2021-12-31166.83$10.93B$65.49M
2021-09-30215.81$13.71B$63.52M
2021-06-30150.86$11B$72.91M
2021-03-31160.23$11.16B$69.67M
2020-12-31144.35$11.39B$78.91M
2020-09-30156$13.66B$87.55M
2020-06-30268.82$21.55B$80.15M
2020-03-31250.1$11.31B$45.24M
2019-12-31231.76$12.65B$54.58M
2019-09-30214.98$5.81B$27.02M
2019-07-01279.03$5.66B$20.28M
2019-06-30283.45$5.75B$20.28M
2019-04-01205.93$5.09B$24.74M
2019-03-31194.84$4.82B$24.74M
2018-12-3185.91$2.92B$33.97M
2018-09-30138.72$5.47B$39.4M
2018-07-01145.49$7.16B$49.23M
2018-06-30145.49$7.16B$49.23M
2018-04-01153.56$8.49B$55.26M
2018-03-31153.6$8.49B$55.24M

Annual Price/Book Ratio

DatePrice/Book RatioMarket capitalizationShareholder equity
2026-06-3071.42$164.99M$2.31M
2025-12-310.04$981,993.56$26.43M
2024-12-31115.52$2.02B$17.5M
2023-12-31100.83$3.74B$37.09M
2022-12-3161.46$4.04B$65.68M
2021-12-31166.83$10.93B$65.49M
2020-12-31144.35$11.39B$78.91M
2019-12-31231.76$12.65B$54.58M
2018-12-3185.91$2.92B$33.97M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
MACROGENICS INC (MGNX)United States$0.242B-20.11
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55